Benchmark Maintains Ligand Pharmaceuticals Incorporated

Benchmark maintained a "Buy" recommendation for Ligand Pharmaceuticals Incorporated (OTCPK:LGNZZ) on November 7, 2025, even as the average one-year price target of $0.08/share suggests a significant 56.31% downside from its latest closing price of $0.18. This conflicting outlook is set against a projected annual revenue decrease of 35.80% to $161 million and an anticipated non-GAAP EPS of $3.99.

Analysis

Benchmark maintained a "Buy" recommendation for Ligand Pharmaceuticals Incorporated (OTCPK:LGNZZ) on November 7, 2025, despite a stark contradiction in its quantitative outlook. The average one-year price target of $0.08/share, ranging from $0.07 to $0.09, implies a substantial 56.31% downside from the latest reported closing price of $0.18/share. This creates a significant disconnect between the analyst's qualitative rating and their own valuation forecast.

The fundamental outlook for LGNZZ appears challenging, with projected annual revenue decreasing by 35.80% to $161 million. While a non-GAAP EPS of $3.99 is projected, this top-line contraction signals considerable headwinds. The overall sentiment surrounding the company's financial trajectory is strongly negative and pessimistic.

Institutional interest in LGNZZ remains notably low and static. Only three funds report positions, holding a total of 29K shares, with no change in holdings or average portfolio weight (0.00%) over the last quarter. This stagnant institutional presence, including major holders like FSMAX and ONEQ, suggests a lack of conviction or significant investment activity.

Key Decisions for Investors

• Thoroughly investigate the significant divergence between Benchmark's "Buy" rating and the implied 56.31% downside from the average price target, as this signals a fundamental inconsistency
• Evaluate the sustainability of the projected $3.99 non-GAAP EPS in light of the substantial 35.80% projected annual revenue decline, indicating potential operational challenges
• Observe institutional positioning for any material changes, given the current minimal and stagnant holdings which reflect limited professional investor conviction